Tag Archives: family offices

Hot Investor Mandate 1: Family Office Creates Investment Arm for Medical Device Companies Based in the U.S.

10 May

A family office arm specializes in investing in and operating medical device companies in which it holds a controlling interest. The firm looks to invest in early and seed stage companies with the goal of investing in 1-2 companies per year to add to its portfolio.

The firm looks to invest in medical device companies that are still in development. The firm prefers technologies subject to the FDA 510(k) pathway, but will consider PMA/combination device and therapeutics if the technology is extremely disruptive. The investors are agnostic with regards to subsector and indication. Current portfolio companies include surgical tools for cardiovascular interventions, consumer health electronics, hospital hardware and therapeutic delivery devices for multiple clinical applications.

The firm looks to invest in companies with great technology that need operational expertise to help advance the technology to market with the goal of leveraging its internal management team for execution of product development, regulatory, and commercial strategy.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , ,

Hot Investor Mandate 1: China-Based Family Office Seeks Global Investment and In-Licensing Opportunities with Focus in USA & UK

26 Apr

A venture capital fund/family office based in Hangzhou, China currently manages two venture funds in addition to a number of private capital accounts through which investments are made – these two funds focus on life sciences. The firm primarily makes equity investments in early-stage rounds ranging from $1 million initially; for later-stage to pre-IPO companies, the firm looks to make initial equity investments ranging from $3-5 million. The firm looks for companies located around the globe, with a preference in the US and Europe (UK). Currently, the firm is also actively seeking in-licensing opportunities in biotech innovations that has a China angle. The firm is actively looking for investment opportunities.

The firm is a flexible and opportunistic investor and will consider therapeutics, medical devices, and diagnostics. The firm is open to all kinds of sectors and indications. For therapeutics, the firm has specific focuses on novel candidates for disease, PD1-base approaches, gene therapy, oncology, cardiovascular diseases, and small molecules. For medical devices, the firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is also interested in diagnostics although this area is less of a focus. In terms of therapeutics, the firm will look at products of pre-clinical stage and later stages from phase II to phase III. Regarding medical devices, the firm will invest at any stage of development.

The firm is looking for private companies only. The firm typically has no specific requirements for the management team, but this depends on how much the firm invests. The firm looks to take a board seat following the investment and is comfortable acting as both a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , ,

Meet the Family Office Panelists at RESI Toronto

5 Apr

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

For every RESI event, the LSN Investor Research team aims to recruit a diverse slate of panels with experienced investors of all types and focus areas within life science technology. As one of the more highly sought types of investors for entrepreneurs, Family Offices is a recurring panel at RESI. Mostly backed by private wealth as evergreen funds, family offices often have deep connections in the life science field both professionally and, at times, personally—some family office investors have loved ones battling debilitating diseases. Family offices are highly idiosyncratic with their own motivations and strategies, though despite their differences and founding stories, they continue to play actively within life science investment.

On April 10th at RESI Toronto, we will hear from four family offices that invest in several different life science sectors. Moderated by Catherine Love, Director of Capital Services for MaRS Discovery District, the panelists include:

  • Sherry Grisewood, Chief Investment Office, Foxhill Asset Management
  • David Ramos, CFO, AGP Holdings
  • Chuck Stetson, CEO, Stetson Family Office
  • Oded Levi, President, Epstein Enterprises

Register now for RESI Toronto at the MaRS Discovery District on April 10th to hear from these experienced individuals.

Tags: , , ,

← Older Entries

%d bloggers like this: